companydata.dkNordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond: Financial statements 2020
CVR: 30197372
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond (CVR 30197372) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK 4,524,460 and a net result of DKK -237,815 compared with DKK 1,316,612 the year before. That is a decrease of 21.3% compared with the year before. Equity amounted to DKK 2,910,775. The solvency ratio was 15.8%. The company had 10 employees in the financial year.
- Gross Profit
- 4,524,460 kr.
- Profit/Loss
- -237,815 kr.
- Equity
- 2,910,775 kr.
- Total Assets
- 18,469,060 kr.
- Employees
- 10
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | 4.5 mio. | -238 t. | 2.9 mio. | 10 |
| 2019 | - | 5.8 mio. | 1.3 mio. | 3.1 mio. | 10 |
How creditworthy is Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond has published its annual report for 2019. Gross profit came to DKK 5,751,063, and the net result was DKK 1,316,612.
About Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond
Nordisk Selskab for Gynækologisk Onkologis Kliniske Forskningsfond is a Danish company of the type Erhvervsdrivende fond based in København Ø, founded in 2006. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kristine Madsen. The company has 2 employees. In 2025, the company reported a gross profit of DKK 7,463,032 and a net result of DKK -334,181 compared with DKK 1,408,745 the year before. Equity amounted to DKK 4,906,927.